Skip to content

Study · Observational study · n = 206 · 2017

4 results

Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

He C, Peng W, Li C, Wen TF

Medicine1 Apr 2017Cited by 11 (Europe PMC)

PMID28422855 (opens in a new tab)PMCIDPMC5406071 (opens in a new tab)DOI10.1097/md.0000000000006606 (opens in a new tab)PepBankPUB-28422855
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-SA. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with small HCC after liver resection, adjuvant Tα1 gave higher overall survival rates than resection alone.

    In plain wordsIn patients with small liver cancer after surgery, adding thymalfasin gave higher survival rates than surgery alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival rate
    Study

    n = 206

    Comparator
    Liver resection alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    5-year OS
    82.9%
    resection + Tα1
    5-year OS
    62.9%
    resection alone

    Source sentences

    Summary
    The 1, 3, and 5-year OS rate of patients in group A was 97.7%, 90.6%, and 82.9%, respectively, and 95.1%, 80.5%, and 62.9%, respectively, for patients in group B (P = .014).
    2 context sentences
    Summary · context
    The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study.
    Summary · context
    Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162).
  2. 02HumanObservational studyEfficacy outcome

    In patients with small HCC after liver resection, adjuvant Tα1 gave higher recurrence-free survival rates than resection alone.

    In plain wordsIn patients with small liver cancer after surgery, adding thymalfasin gave more time without recurrence than surgery alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRecurrence-free survival rate
    Study

    n = 206

    Comparator
    Liver resection alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    5-year RFS
    53.3%
    resection + Tα1
    5-year RFS
    32.1%
    resection alone

    Source sentences

    Summary
    The 1, 3, and 5-year RFS rate of patients in group A was 70.5%, 56.8%, and 53.3%, respectively, and 65.8%, 41.3%, and 32.1%, respectively, for patients in group B (P = .015).
    2 context sentences
    Summary · context
    The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study.
    Summary · context
    Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162).
  3. 03HumanObservational studyEfficacy outcome

    In patients with small HCC after liver resection, Tα1 was an independent prognostic factor for overall survival, with a lower risk of death (hazard ratio 0.349).

    In plain wordsIn patients with small liver cancer after surgery, thymalfasin was linked to a lower risk of death after other factors were considered.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseOverall survival hazard ratio (multivariate)
    Study

    n = 206

    Comparator
    Liver resection alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio for OS
    0.349
    multivariate analysis

    Source sentences

    Summary
    Multivariate analysis indicated that Tα1 was an independent prognostic factor for both OS (P = .015, hazard ratio 0.349, 95% confidence interval 0.149-0.816) and RFS (P = .019, hazard ratio 0.564, 95% confidence interval 0.349-0.910)
    2 context sentences
    Summary · context
    The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study.
    Summary · context
    Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162).
  4. 04HumanObservational studyEfficacy outcome

    In patients with small HCC after liver resection, Tα1 was an independent prognostic factor for recurrence-free survival, with a lower risk of recurrence or death (hazard ratio 0.564).

    In plain wordsIn patients with small liver cancer after surgery, thymalfasin was linked to a lower risk of recurrence after other factors were considered.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseRecurrence-free survival hazard ratio (multivariate)
    Study

    n = 206

    Comparator
    Liver resection alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio for RFS
    0.564
    multivariate analysis

    Source sentences

    Summary
    Multivariate analysis indicated that Tα1 was an independent prognostic factor for both OS (P = .015, hazard ratio 0.349, 95% confidence interval 0.149-0.816) and RFS (P = .019, hazard ratio 0.564, 95% confidence interval 0.349-0.910)
    2 context sentences
    Summary · context
    The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection.A total of 206 patients with small HCC who underwent liver resection were analyzed in our retrospective cohort study.
    Summary · context
    Patients were divided into 2 groups: group A (resection + Tα1, n = 44) and group B (resection, n = 162).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.